Ascendis Pharma Bone Diseases A/S – Trademark Portfolio
Entity Type: 99
Ascendis Pharma Bone Diseases A/S holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 3 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include ODJOY, ONJUNU, and ELISPHYRE. The owner is based in Hellerup.
Hellerup 2900 , DK
Showing of trademarks Trademarks
Trademark Classifications
Ascendis Pharma Bone Diseases A/S's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Ascendis Pharma Bone Diseases A/S have?
Ascendis Pharma Bone Diseases A/S has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.
What trademark classes does Ascendis Pharma Bone Diseases A/S file in?
Ascendis Pharma Bone Diseases A/S files trademarks across 3 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are Ascendis Pharma Bone Diseases A/S's most well-known trademarks?
Ascendis Pharma Bone Diseases A/S's registered trademark portfolio includes well-known marks such as ODJOY, ONJUNU, and ELISPHYRE. These are among 3 currently registered trademarks in the portfolio.
What is Ascendis Pharma Bone Diseases A/S's trademark registration success rate?
Ascendis Pharma Bone Diseases A/S has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.